Recombinant Rat CDKN2A Protein，His

The CDKN2A gene, located on chromosome 9, plays a critical role in cell cycle regulation by encoding two proteins, p16^INK4a and p14^ARF, both of which are crucial for tumor suppression. Mutations and deletions in CDKN2A are frequently observed in various cancers, including melanoma, pancreatic cancer, and lung cancer, highlighting its significance as a tumor suppressor. Recent studies have shown that recombinant proteins derived from CDKN2A, particularly p16^INK4a, can be utilized in therapeutic applications and cancer diagnostics. By producing CDKN2A recombinant proteins in laboratory settings, researchers can investigate their interactions with cyclin-dependent kinases and other cell cycle regulators, paving the way for new cancer treatments. Additionally, such proteins have potential applications in the development of vaccines and other immunotherapeutic strategies aimed at enhancing anti-tumor immunity. Understanding the structural and functional properties of CDKN2A recombinant proteins is essential for elucidating their role in oncogenesis and for designing effective interventions. Therefore, ongoing research in this area continues to refine and expand our knowledge of CDKN2A's implications in cancer biology, potentially leading to novel strategies for targeting this important pathway in cancer treatment and prevention.